Psychedelic/entactogen-assisted therapy for treatment of anxiety, depression and existential distress in adult palliative care
Sivan Schipper, Kabir Nigam, Vanessa Piechotta, Michael Ljuslin, Yvan Beaussant, Guido Schwarzer, Christopher Boehlke
Cochrane Database of Systematic Reviews November 21, 2022 DOI: 10.1002/14651858.cd015383 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review protocol Peer reviewed |
|---|---|
| Population | Adult palliative care patients |
| Intervention | Psychedelic/entactogen-assisted therapy |
| Topics | Anxiety Depression End-of-life distress Psychedelic-assisted therapy |
| Keywords | Distress Depression economics Palliative care Psychotherapist Intervention counseling Placebo Existentialism Clinical psychology Alternative medicine Nursing |
| Citations | 4 |
| Key findings | The protocol sets out the objectives and methods for a future Cochrane Review, aiming to assess the benefits and harms of psychedelic/entactogen-assisted therapy versus placebo or active comparators for anxiety, depression, and existential distress in adult palliative care. No findings are reported as this is a protocol. |
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of psychedelic/entactogen‐assisted therapy compared to placebo or active comparators (e.g. antidepressants) for treatment of anxiety, depression, and existential distress in adult palliative care.